Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model

Table 2 Adverse effects and mortality after cell transplantation

Cell type	Cell dose	Cell-related adverse effects after transplantation		% Mortality (number of deaths/total number) after transplantation
Cell type	Cell dose	< 24 hours	>24 hours	<24 hours	>24 hours
cbMNCs	10 × 10⁶	None	None	0 (Nonsignificant)	8% (2/24) (Nonsignificant)
cmMSCs	10 × 10⁶	3/6 animals developed severe inflammation in ipsilateral eye	None	100% (6/6) *P < 0.0001	_
cmMSCs	5 × 10⁶	1/23 animals developed severe inflammation in ipsilateral eye	None	0 (Nonignificant)	26% (6/23) (Nonsignificant)
cbMSCs	5 × 10⁶	None	None	0 (Nonsignificant)	11% (2/18) (Nonsignificant)

Adverse effects and mortality after cell transplantation. The table shows cell-related adverse effects within 24 hours and >24 hours of cell transplantation. Both cbMNC- and cbMSC-group animals had no adverse effects after cell transplantation. One animal transplanted with 5 × 10⁶ cmMSCs and three animals transplanted with 10 × 10⁶ cmMSCs had severe inflammation of the ipsilateral eye within 24 hours of transplantation. The mortality rate was calculated, for two time points, within 24 hours and >24 hours, as a percentage of animals that died to the total animals in each group. A decreasing trend in mortality was seen in the cbMNC and cbMSC groups, but not in the cmMSC group compared with the PBS group. The mortality rate within 24 hours of transplantation in animals transplanted with 10 × 10⁶ cmMSCs was significantly higher compared with the PBS group animals (P < 0.0001). *P value relative to the PBS group calculated with the Fisher Exact test. Significance was ascertained at P < 0.05.

ISSN: 1757-6512